Patients with Atrial Fibrillation are Unlikely to Benefit from Aspirin Monotherapy
Nan Wang,Qiqi Hou,Shouling Wu,Quanle Han,Kangbo Li
DOI: https://doi.org/10.2147/ijgm.s444036
IF: 2.145
2024-05-23
International Journal of General Medicine
Abstract:Nan Wang, 1 Qiqi Hou, 2 Shouling Wu, 3 Quanle Han, 4 Kangbo Li 5 1 Catheterization Unit, Tangshan Gongren Hospital, Tangshan, People's Republic of China; 2 Hebei Medical University, Shijiazhuang, People's Republic of China; 3 Department of Cardiology, Kailuan General Hospital, Tangshan, People's Republic of China; 4 Department of Cardiology, Tangshan Gongren Hospital, Tangshan, People's Republic of China; 5 School of Clinical Medicine, North China University of Science and Technology, Tangshan, People's Republic of China Correspondence: Quanle Han, Email Background: Aspirin (ASA), the mainstay antiplatelet treatment in patients with cardiovascular disease (CVD), has been received by a considerable number of AF patients. This study sought to examine the association between ASA monotherapy and the risk of major adverse cardiac and cerebrovascular events (MACCE) in patients with atrial fibrillation (AF). Methods: A total of 850 patients with AF were identified from a community-based Kailuan study. All patients were assigned to two groups according to their medicine history: an aspirin therapy group (ASA group) (n = 174), and a non-aspirin therapy group (non-ASA group) (n = 676). The clinical endpoints are MACCE, including myocardial infarction (MI), ischemic stroke (IS), and hemorrhagic stroke (HS). Incidence curves for MACCE were plotted using the Kaplan–Meier method, and the Log rank test was used to assess the differences in incidence rates. The hazard ratios (HR) and 95% confidence intervals (CI) for MACCE were analyzed using Cox proportional-hazards analysis regression models. Results: During the 7.2-year follow-up, 30 MACCE occurred in the ASA group, and 101 in the non-ASA group, with a cumulative incidence of 19.88% vs 17.27%, P = 0.511; 3 cases of MI occurred in the ASA group, and 18 cases in the non-ASA group, with a cumulative incidence of 1.78% vs 2.90%, P = 0.305. Twenty-seven cases of IS occurred in the ASA group, and 84 cases in the non-ASA group, with a cumulative incidence of 1.78% vs 2.90%, P = 0.305. Eight cases of HS occurred in the ASA group, and 13 cases in the non-ASA group, with a cumulative incidence of 5.01% vs 2.34%, P = 0.045. Multivariate regression analysis showed that ASA therapy was not associated with MACCE (HR: 1.130, 95% CI: 0.747– 1.710, P = 0.562). In addition, ASA therapy was not associated with IS (HR: 1.309, 95% CI: 0.843– 2.034, P = 0.231). However, ASA therapy was significantly associated with HS (HR: 2.563, 95% CI: 1.024– 6.418, P = 0.044). Conclusion: ASA monotherapy is not associated with a lower risk of ischemic events, while significantly associated with a higher risk of bleeding events. Patients with AF are unlikely to benefit from aspirin monotherapy. Keywords: atrial fibrillation, aspirin monotherapy, major adverse cardiac and cerebrovascular events, myocardial infarction, ischemic stroke, hemorrhagic stroke Atrial fibrillation (AF) is the most common cardiac arrhythmia, and the leading cause of cardioembolic stroke, 1,2 with a prevalence ranging from 0.1% in patients below 55 years to over 9% in octogenarian patients, and fivefold elevation in the risk of ischemic stroke (IS) among individuals with AF. 3 It has been well accepted that oral anticoagulants substantially reduce the risk for IS in patients with AF determined to be at intermediate to high risk for thromboembolism. 4 The latest guidelines consider that antiplatelet therapy is not recommended for stroke prevention in AF patients. 5,6 Despite that, aspirin (ASA), the mainstay antiplatelet treatment in patients with cardiovascular disease (CVD), has been received by a considerable number of AF patients. 7 It has been reported that AF patients with concomitant stable coronary artery disease are also likely to receive combined antiplatelet and anticoagulant therapy. 8–10 Therefore, this study sought the association between ASA monotherapy and the risk of major adverse cardiac and cerebrovascular events (MACCE) in patients with AF. The Kailuan study is an ongoing prospective community-based cohort study to investigate the risk factors for cardiovascular and cerebrovascular diseases in the city of Tangshan, China. The study participants are the employees and retirees from the Kailuan Group. Participants were originally recruited for physical examination. The present study is based on the data of Kailuan study from the year of 2014 to 2016. Based on the recorded medical histories, patients with AF were selected for our present study as per the relevant diagnostic criteria. 11 The clinical endp -Abstract Truncated-
medicine, general & internal